Jan Baptist Vermorken
Overview
Explore the profile of Jan Baptist Vermorken including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
185
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zaryouh H, De Pauw I, Baysal H, Melis J, Van den Bossche V, Hermans C, et al.
Cancer Drug Resist
. 2024 Jan;
6(4):709-728.
PMID: 38239393
Acquired resistance to the targeted agent cetuximab poses a significant challenge in finding effective anti-cancer treatments for head and neck squamous cell carcinoma (HNSCC). To accurately study novel combination treatments,...
2.
Zaryouh H, Van Loenhout J, Peeters M, Vermorken J, Lardon F, Wouters A
Cancers (Basel)
. 2022 Dec;
14(24).
PMID: 36551613
Resistance to EGFR-targeted therapy is a major obstacle on the road to effective treatment options for head and neck cancers. During the search for underlying mechanisms and regulators of this...
3.
Baysal H, Siozopoulou V, Zaryouh H, Hermans C, Lau H, Lambrechts H, et al.
Front Immunol
. 2022 Oct;
13:1001161.
PMID: 36268020
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of tumors that retain their poor prognosis despite recent advances in their standard of care. As the involvement of...
4.
Zaryouh H, De Pauw I, Baysal H, Pauwels P, Peeters M, Vermorken J, et al.
Front Oncol
. 2021 Sep;
11:697967.
PMID: 34568028
The epidermal growth factor receptor (EGFR) is a therapeutic target in head and neck squamous cell carcinoma (HNSCC). Resistance to EGFR-targeted therapies, such as cetuximab, poses a challenging problem. This...
5.
Baysal H, De Pauw I, Zaryouh H, Peeters M, Vermorken J, Lardon F, et al.
Front Immunol
. 2021 Sep;
12:737311.
PMID: 34557197
Cetuximab has an established role in the treatment of patients with recurrent/metastatic colorectal cancer and head and neck squamous cell cancer (HNSCC). However, the long-term effectiveness of cetuximab has been...
6.
Zaryouh H, De Pauw I, Baysal H, Peeters M, Vermorken J, Lardon F, et al.
Med Res Rev
. 2021 Apr;
42(1):112-155.
PMID: 33928670
Resistance to therapies targeting the epidermal growth factor receptor (EGFR), such as cetuximab, remains a major roadblock in the search for effective therapeutic strategies in head and neck squamous cell...
7.
Yang K, Xu C, Chen Y, Vermorken J, OSullivan B, Ma J
Front Oncol
. 2021 Mar;
11:647809.
PMID: 33768007
No abstract available.
8.
Baysal H, De Pauw I, Zaryouh H, De Waele J, Peeters M, Pauwels P, et al.
Br J Cancer
. 2020 Jun;
123(5):752-761.
PMID: 32541873
Background: The epidermal growth factor receptor (EGFR) is overexpressed by 80-90% of squamous cell carcinoma of head and neck (HNSCC). In addition to inhibiting EGFR signal transduction, cetuximab, a monoclonal...
9.
Van den Bossche J, Domen A, Peeters M, Deben C, De Pauw I, Jacobs J, et al.
Cancers (Basel)
. 2019 Dec;
11(12).
PMID: 31795121
Polo-like kinase 1 (Plk1), a master regulator of mitotic cell division, is highly expressed in non-small cell lung cancer (NSCLC) making it an interesting drug target. We examined the in...
10.
Rognoni C, Quaglini S, Vermorken J, De Cecco L, Licitra L, Bossi P
Clin Ther
. 2019 Oct;
41(12):2517-2528.e28.
PMID: 31630814
Purpose: Patients with recurrent and/or metastatic head and neck squamous cell cancer are offered platinum-based chemotherapy plus cetuximab; however, this strategy is not cost-effective. We evaluated the cost-effectiveness of a...